

Elkin Vladimir Lemos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3595649/publications.pdf>

Version: 2024-02-01

33
papers

1,155
citations

933447

10
h-index

752698

20
g-index

38
all docs

38
docs citations

38
times ranked

1938
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant <i>Klebsiella pneumoniae</i> in Colombia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 235-240.	1.4	6
2	In vitro activity of ceftazidime-avibactam against Enterobacterales and <i>Pseudomonas aeruginosa</i> isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 1016-47.	0.6	10
3	Candidemia en Colombia. <i>Biomedica</i> , 2020, 40, 195-207.	0.7	19
4	Risk of infection in patients undergoing urologic surgery based on the presence of asymptomatic bacteriuria: A prospective study. <i>American Journal of Infection Control</i> , 2019, 47, 1474-1478.	2.3	6
5	Factors associated with multidrug-resistant bacteria in a cohort of patients with asymptomatic bacteriuria who underwent urological surgery. <i>American Journal of Infection Control</i> , 2019, 47, 1479-1483.	2.3	4
6	PIN25 CALIDAD DE REVISIONES SISTEMATICAS CON EVALUACIONES DE COSTO-EFECTIVIDAD DE LA VACUNA CONTRA ROTAVIRUS DE PAISES LATINOAMERICANOS. <i>Value in Health Regional Issues</i> , 2019, 19, S44.	1.2	0
7	Mortality due to KPC carbapenemase-producing <i>Klebsiella pneumoniae</i> infections: Systematic review and meta-analysis. <i>Journal of Infection</i> , 2018, 76, 438-448.	3.3	62
8	Duration of surgical antibiotic prophylaxis in patients with asymptomatic bacteriuria. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 370.	9.1	3
9	<i>Escherichia Coli</i> productora de Nueva Delhi metalo- β -lactamasa en Colombia: reporte de caso. <i>Infectio</i> , 2017, 21, .	0.4	0
10	Evaluacion Economica De Los Principales Esteroides Intranasales Utilizados Para El Tratamiento De Pacientes Pediatricos Con Rinitis Alergica En Colombia. <i>Value in Health</i> , 2015, 18, A840.	0.3	0
11	Assessing the Public Health Impact and Cost Effectiveness of Pneumococcal Vaccines for Adults 65 Years of Age in Colombia. <i>Value in Health</i> , 2015, 18, A871.	0.3	3
12	Cost-Effectiveness Analysis of Mometasone Furoate Versus Beclomethasone Dipropionate for the Treatment of Pediatric Allergic Rhinitis in Colombia. <i>Advances in Therapy</i> , 2015, 32, 254-269.	2.9	8
13	Carbapenem resistance and mortality in patients with <i>Acinetobacter baumannii</i> infection: systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2014, 20, 416-423.	6.0	218
14	International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module. <i>American Journal of Infection Control</i> , 2014, 42, 942-956.	2.3	233
15	Impact of carbapenem resistance on clinical and economic outcomes among patients with <i>Acinetobacter baumannii</i> infection in Colombia. <i>Clinical Microbiology and Infection</i> , 2014, 20, 174-180.	6.0	41
16	Cost-Effectiveness Of Ertapenem Versus Piperacillin/Tazobactamin In Treating Community Acquired Intra-Abdominal Infections In Colombia. <i>Value in Health</i> , 2014, 17, A273.	0.3	0
17	Cost-Effectiveness Of Ertapenem Versus Ceftriaxone In Treating Urinary Tract Infections In Colombia. <i>Value in Health</i> , 2014, 17, A274.	0.3	0
18	Frequency of microorganisms isolated in patients with bacteremia in intensive care units in Colombia and their resistance profiles. <i>Brazilian Journal of Infectious Diseases</i> , 2013, 17, 346-352.	0.6	18

#	ARTICLE	IF	CITATIONS
19	Healthcare expenses associated with multiple vs singleton pregnancies in the United States. American Journal of Obstetrics and Gynecology, 2013, 209, 586.e1-586.e11.	1.3	91
20	Costo-Efectividad Del Uso De Pruebas Treponémicas Rápidas Para La Detección Y Tratamiento Temprano De Sífilis Gestacional En Colombia. Value in Health, 2013, 16, A668.	0.3	0
21	Assessment of Burden of Illness Due to Herpes Zoster in Argentina: A Prospective Observational Study. Value in Health, 2013, 16, A668.	0.3	5
22	Comparison of Gonadotropin Utilization between GnRH Agonist and Antagonist Protocols – A Meta-analysis. Fertility and Sterility, 2013, 99, S18.	1.0	0
23	PIN31 Cost-Effectiveness Analysis of Antifungal Treatments Available in Colombia for the Treatment of Invasive Candidiasis. Value in Health, 2012, 15, A242.	0.3	0
24	International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. American Journal of Infection Control, 2012, 40, 396-407.	2.3	356
25	PIN36 Cost-Effectiveness Analysis of Voriconazole Versus Amphotericin B Deoxycholate in the Treatment of Invasive Pulmonary Aspergillosis in Colombia. Value in Health, 2012, 15, A243.	0.3	0
26	PIN27 COST-EFFECTIVENESS ANALYSIS OF THE THERAPY FOR THE INVASIVE ASPERGILLOSIS IN COLOMBIA. Value in Health, 2010, 13, A191.	0.3	0
27	Cost-effectiveness analysis of the therapy for the invasive Candidiasis in Colombia. International Journal of Infectious Diseases, 2010, 14, e123.	3.3	0
28	The economic impact of introducing HIV/AIDS guideline into Colombian National Drug Formulary. Cost-effectiveness analysis. International Journal of Infectious Diseases, 2010, 14, e242-e243.	3.3	9
29	PIN4 ANTIMICROBIAL RESISTANCE PREVALENCE OF ENTEROCOCCI FROM BOGOTA, COLOMBIA HOSPITALS 2001-2006. Value in Health, 2008, 11, A93.	0.3	0
30	PIN12 PHARMACOECONOMIC ANALYSIS BASED ON GUIDELINES FOR TREATING MILD DIABETIC FOOT INFECTIONS: A DECISION TREE MODEL FOR COLOMBIA. Value in Health, 2008, 11, A95-A96.	0.3	0
31	PIN22 PHARMACOECONOMIC ANALYSIS BASED ON GUIDELINES FOR TREATING MILD DIABETIC FOOT INFECTIONS: A DECISION TREE MODEL FOR CANADA. Value in Health, 2008, 11, A98-A99.	0.3	0
32	Management and Prevention of Diabetic Foot Ulcers and Infections. Pharmacoeconomics, 2008, 26, 1019-1035.	3.3	55
33	Highlights from the 45th IDSA annual meeting. Lancet Infectious Diseases, The, 2007, 7, 769.	9.1	0